MADISON, Wis., Aug. 23 /PRNewswire/ -- Mirus Bio Corporation today announced that it has been awarded five federal grants and contracts since January of this year totaling $5.4 million. They include:
-- Two Phase II SBIR grants totaling $2.4 million to further develop the
Company's Dynamic PolyConjugates(TM) siRNA delivery platform and
alternative nanoparticle technologies, focused primarily on improving
potency for liver applications;
[Principal Investigators Drs. D. Rozema and S. Wong]
-- One Phase II DOD contract for $1.8 million to optimize the Dynamic
PolyConjugates(TM) siRNA delivery platform for lung delivery and to
develop a treatment against respiratory infections;
[Principal Investigator Dr. H. Herweijer]
-- A Phase I SBIR grant for $0.3 million to improve gene expression
[Principal Investigator Dr. M. Sebestyen]
-- A previously announced Phase II SBIR grant for $0.9 million to develop
improved labeling technologies for microRNA, which is expected to lead
to new research products.
[Principal Investigator Dr. M. Watt]
"Securing this magnitude of support highlights the wide breadth of potential uses for this platform delivery technology and is a tribute to the outstanding cutting edge technology development being done by our research team," commented Jon Wolff, M.D., Mirus Bio's CSO and co-founder. "In this era of heightened competition for federal research grants, we are exceptionally pleased with this outcome and couldn't be more proud of our team as well as the grant procurement management that Dr. Hans Herweijer has provided. These funds are critical to maintaining our leadership position in nucleic acid delivery technologies."
Dynamic PolyConjugates(TM) (DPC) are an enabling platform for the
targeted, systemic delivery of small interfering RNA (siRNA), a
|SOURCE Mirus Bio Corporation|
Copyright©2007 PR Newswire.
All rights reserved